Drug Profile
Tucatinib - Array BioPharma/Seagen
Alternative Names: ARRY 380; Irbinitinib; MK 7119; ONT 380; TUKYSALatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Criterium; Merck & Co; Merck Sharp & Dohme; Novartis; Seagen
- Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Oxazoles; Pyridines; Quinazolines; Small molecules; Triazoles
- Mechanism of Action ERBB 2 receptor antagonists; Phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; HER2 positive breast cancer
- Phase II/III Gastrointestinal cancer
- Phase II Biliary cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Phase I/II Cholangiocarcinoma; Gallbladder cancer
Most Recent Events
- 12 Feb 2024 Phase-II clinical trials in Urogenital cancer (Second-line therapy or greater, Metastatic disease) (PO), prior to February 2024 (Pfizer pipeline, February 2024)
- 07 Feb 2024 Seagen initiates a phase Ib/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA(PO) (NCT06157892)
- 18 Jan 2024 Efficacy and adverse event data from a phase I/II trial in Gastrointestinal cancer presented at the Gastrointestinal Cancers Symposium 2024 (ASCO-GCS-2024)